With so many of our members being touched by the effects of cancer, we are pleased to announce the Vision Super Snowdome Foundation Fellowship, a three year funding partnership with the Snowdome Foundation.
The fellowship will help expand access to genetic testing for blood cancer patients at the Peter MacCallum Cancer Centre. This testing can be life-changing for patients who don’t respond well to standard therapy, guiding them to alternative treatments, drugs and clinical trials.
This testing is at the core of the emerging field of ‘personalised medicine’ for blood cancers,” said Peter Mac’s Clinical and Laboratory Haematologist Dr Piers Blombery, who performs the testing and leads the program.
The Snowdome Foundation works to channel government and philanthropic investment into early phase human clinical trials of next generation drugs and therapies. They have been widely recognised for their innovative work, winning the inaugural National Charity Award at the 2016 Telstra Business Awards.
As well as this new funding, Vision Super staff raised over $15,000 for Snowdome earlier this year through our participation in the Murray to Moyne bike ride.
Just as in the general population, cancer affects many of our members. About quarter of our total and permanent disability claims are cancer-related and in almost half of paid life insurance claims where a member has passed away, the death was caused by cancer,” Vision Super CEO Stephen Rowe said.
“A huge part of what we do is assisting our members and their families who are impacted by cancer today.
“But there is also an important role we can and should play supporting the work of Australia’s world-leading cancer researchers and clinicians who are focused on reducing the personal, social and economic impact cancer in our communities now and into the future.”
Researchers conducting life-changing genetic testing for blood cancer patients.
Patients, like Paul Omond, are already benefiting from the genetic testing. Paul was diagnosed with a rare blood cancer in 2012 and experienced severe side effects from conventional therapy.
The genetic testing lead him to a drug specifically targeted to his leukaemia gene mutation.
“I’m now able to live life on my terms and not be controlled by a disease, and words cannot describe how lucky I am that this type of treatment is available,” Paul said.
Director of Snowdome, Professor Richard Boyd thanked Vision Super for allowing Dr Blombery to pursue his ground breaking research and “making hope real” for Australians suffering hard-to-treat blood cancers.
To find out more about the Snowdome Foundation, please see their website.